Breaking the Myb–KIX Alliance: Structure‐Guided Discovery of Biaryl Hydroxy‐Naphthamides as Disruptors of the c‐Myb–CBP/p300 KIX Protein–Protein Interaction
Aug 2026· Archiv der Pharmazie· Vol 359· 0 citations· 32 references
Medicine
TL;DR
3‐hydroxy‐2‐naphthamides are established as promising scaffolds for targeting the c‐Myb–CBP/p300 KIX interface and are supported as the most conformationally stable interfacial binders.
Abstract
The interaction between the transcription factor c‐Myb and the CBP/p300 KIX domain is a critical regulatory node in hematopoietic gene expression and an attractive target in MYB‐dependent leukemia. Herein, we aimed to identify new small‐molecule disruptors of the c‐Myb–CBP/p300 KIX protein–protein interaction using integrated in silico and experimental workflow. A focused library of 1143 biaryl hydroxy‐naphthamides (naphthanilides) was subjected virtual screening filters yielding five prioritized candidates (C1–C5). Docking showed that all selected compounds occupied the c‐Myb‐facing groove of the KIX domain and reproduced key interfacial contacts. Subsequent 1000 ns molecular dynamics simulations revealed distinct stability and disruption profiles, with C1 and C4 showing the most favorable combination of stable groove occupancy, protein–protein interface perturbation, and ligand‐binding energetics. Free‐energy landscape analysis further supported these compounds as the most conformationally stable interfacial binders. Differential MM/PBSA analysis of the protein–protein interface showed that C1 produced the largest predicted weakening of the c‐Myb–KIX interaction (ΔΔGPPI = +38.81 kcal/mol), followed by C4 (+29.90), C5 (+27.78), and C3 (+25.81 kcal/mol), whereas C2 was predicted to stabilize the complex (−5.41 kcal/mol). In silico ADMET profiling indicated that the series was drug‐like by Lipinski criteria but carried liabilities related to solubility, metabolism, and predicted toxicity. Experimental validation by microscale thermophoresis confirmed direct binding of the assay proteins (Kd = 26.72 ± 0.82 µM) and demonstrated that the naphthanilides disrupt the interaction in vitro. C1 was the most potent disruptor (IC50 = 9.50 ± 0.22 µM), outperforming Naphthol AS‐E phosphate (IC50 = 32.84 ± 9.46 µM). These findings establish 3‐hydroxy‐2‐naphthamides as promising scaffolds for targeting the c‐Myb–CBP/p300 KIX interface.
Findings identify Fumiquinazoline D as an early‐stage biochemical hit for disruption of the Skp2–Cks1 interaction and as a potential scaffold for further mechanistic validation and medicinal‐chemistry investigation.
Emadeldin M. Kamel, A. A. Allam, H. Rudayni et al.· ChemMedChem· 0 citations
Tingenone is identified as a promising scaffold for the development of new c-Myb-CBP/p300 KIX PPI inhibitors, having produced the clearest signatures of interfacial weakening and the most favorable disruption metrics.
Emadeldin M. Kamel, H. Rudayni, A. A. Allam et al.· Journal of Molecular Graphic...· 0 citations
Findings validate the diphenylpyrazine scaffold as a promising chemotype for Skp2–Cks1 inhibition and identify C3 as a strong lead for further optimization.
Emadeldin M. Kamel, A. A. Allam, H. Rudayni et al.· Journal of Computer-Aided Mo...· 0 citations
The interaction between c-Myb and the CBP/p300 KIX domain is a critical transcriptional regulatory event and an attractive target for the development of candidate disruptors of the recombinant c-Myb-KIX interaction. In this study, we used an integrated computational and experimental strategy to identify new small molec...
Emadeldin M. Kamel, H. Rudayni, A. A. Allam et al.· Biophysical Chemistry· 0 citations
The SARS‐CoV‐2 nucleocapsid (N) protein is a key regulator of viral genome packaging and replication, making it an attractive antiviral target. Here, we provide structural and energetic insights into N‐protein inhibition using molecular docking, pharmacophore screening, molecular dynamics (MD) simulations, and MM‐PBS...
Srimai Vuppala, Jaeyoung Kim, Mengdi Zhao et al.· Bulletin of the Korean Chemi...· 0 citations
HFS764 disrupts the HIF-1α–p300 interface and suppresses hypoxia-driven signaling in ccRCC, supporting the use of transcriptional complex inhibition as a promising therapeutic strategy.
Mesfer Al Shahrani· Discover medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.